Picture [iito] Männer Ballett 650x80px
Organisation › Details

ThromboGenics N.V. (Euronext Brussels: THR)

ThromboGenics is a biotechnology company focused on discovery and development of biopharmaceuticals for the treatment of a range of vascular diseases. The Company has several programs in Phase II clinical development including microplasmin, which is being evaluated as a treatment for vitreoretinal disorders and as a thrombolytic agent for vascularocclusive diseases, including acute stroke. ThromboGenics also has one program, TB-402 (Anti-Factor VIII), in Phase I clinical trials, and three other drug candidates in preclinical development with preclinical proof-of-principle demonstrated. ThromboGenics has built strong links with the University of Leuven and has exclusive rights to certain therapeutics developed at the University. ThromboGenics is headquartered in Leuven, Belgium and has subsidiaries in Dublin,Ireland and New York, U.S. The Company is listed on Eurolist by Euronext Brussels under the symbol THR. *


Period Start 2004-10-12 existent
Period End 2018-09-10 renamed
  Group Oxurion (Group)
  Today Oxurion N.V. (Euronext Brussels: OXUR)
  Predecessor University of Leuven (KU Leuven, Katholieke Universiteit Leuven)
  Successor Oxurion N.V. (Euronext Brussels: OXUR)
Products Industry biopharmaceutical
  Industry 2 Jetrea®
Persons Person De Haes, Patrik (ThromboGenics 200808– CEO before Roche Diagnostics)
  Person 2 Buyse, Chris (Fund+ 201610 Managing Partner before ThromboGenics 201203 CFO)
Region Region Leuven (Louvain)
  Country Belgium
  Street 49 Campus Gasthuisberg, Herestraat
  City 3000 Leuven
  Tel +32-16-346-194
    Address record changed: 2018-07-24
Basic data Employees n. a.
  Currency EUR
  Annual sales 7,104,000 (income, consolidated (2016) 2016-12-31)
  Profit -60,348,000 (2016-12-31)
  Cash 113,400,000 (2017-09-30)
    * Document for �About Section�: 
Record changed: 2018-10-30


Picture ConsulTech GmbH GDPR-compliant E-Col Cloud Document Management 650x80px

More documents for Oxurion (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture EBD Group BioPharm America 2020 Digital Event BEU2020 650x81

» top